Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma
NEW YORK and PETAH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:...
Vaccine
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
Submission follows application for Omicron BA.1-adapted bivalent vaccine submitted in July If authorized, both Omicron BA.1-adapted and Omicron BA.4/5-adapted bivalent...
Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration Complete BLA Submission on Track for Fourth Quarter...
U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness
RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S....
Bavarian Nordic Enters Supply Agreement with PAHO to Support Access to Monkeypox Vaccines in Latin America and the Caribbean
Agreement enables PAHO countries to access the vaccine in 2022 through PAHO’s Revolving Fund for Access to VaccinesCOPENHAGEN, Denmark, August...
Bavarian Nordic Announces First Half 2022 Results
COPENHAGEN, Denmark, August 24, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress...
Sorrento Announces Significant Positive Pivotal Trial Results as Assessed by an Independent Review Committee (IRC) With Matured Long-Term (Over Three Years) Follow-Up Data of Abivertinib for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Abivertinib is a novel third-generation epidermal growth factor receptor (EGFR) inhibitor that irreversibly targets mutant forms of EGFR in advanced...
mRNA Leading Expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers Investing EUR 39M Series B2 Financing in mRNA Technology Platform Company eTheRNA
Financing round led by Novalis LifeSciences LLCBoth investors Dr. Marijn Dekkers and Moderna’s co-founder Dr. Kenneth Chien to join the...
NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory
Further Enhances Research Capabilities in Infectious Disease and BiodefenseDURHAM, N.C., Aug. 23, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American:...
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
Updated analysis from 34 cases occurring at least seven days following a three-dose regimen showed 73.2% vaccine efficacy among children...
Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration
MIAMI, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets
World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated...
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID
Results from Planned Interim Analysis Expected First Half 2023 Long COVID Afflicts More Than 30% of Patients Following Infection with...
Todos Medical Announces Commercialization of Lesion and Saliva-Based MonkeyPox PCR Testing
Provista begins validation preparations for blood-based IgM/IgG MonkeyPox LDTCompany to release its Q2/2022 10Q quarterly report at 4:05 pm ET...
Sorrento Therapeutics Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients
STI-1558, an oral SARS-CoV-2 main protease (Mpro) inhibitor, which can block viral replication, is specifically designed as a standalone treatment...
Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients
MIAMI, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update
Oslo, August 19, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its second...
Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido® across certain designated territories including Middle East and North Africa
PALO ALTO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing...
Blue Water Vaccines Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate
CINCINNATI, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a...
Scilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Work To Access An Additional 20 Million Lives With One Of The Largest National Pharmacy Benefit Managers (PBMs) For ZTlido® (lidocaine topical system) 1.8%
30 million lives now covered by one of the largest national PBMsContinue to work with this PBM to access an...